Unable to display view head.php file not found.
« Prev
Next »
 
 

Barter - Figure 22 - Future of CETP inhibition

With all of this evidence:

What is the future of CETP inhibition as an anti-atherogenic strategy? As listed in the Figure, there appears to be a compelling case for further testing the hypothesis that inhibiting CETP will be anti-atherogenic in humans, so long as the hypothesis is tested with inhibitors that do not share the off-target pharmacology of torcetrapib. To prove this, it will be necessary to investigate this hypothesis in clinical outcome trials.

Barter P. J Clin Lipidol. 2011; 5(6).
Unable to display view foot.php file not found.